Navigation Links
MicroRNA-218 targets medulloblastoma, most aggressive childhood brain cancer
Date:12/13/2012

Between the blueprint of the genome and the products of its expression lie microRNAs, which can boost or lower the rate at which genes become stuff. In fact, many cancers use microRNA to magnify the expression of faulty genes or shrink the expression of helpful genes that would otherwise suppress tumors. A University of Colorado Cancer Center study published in the December issue of the Journal of Biological Chemistry shows that in medulloblastoma, a malignant brain tumor of children, microRNA-218 is especially low. The article also shows that adding microRNA-218 to neural stem cells engineered to develop medulloblastoma decreases the development of the cancer.

"For the past five years, we've been looking at microRNAs in medulloblastoma, asking how they are normally expressed and how this expression differs in the disease. One of the microRNA's most different in the medulloblastoma is microRNA-218," says Rajeev Vibhakar, MD, PhD, MPH, investigator at the CU Cancer Center, assistant professor of pediatrics at the CU School of Medicine, and the paper's senior author.

When Vibhakar and colleagues inquired into the effects of lower microRNA-218 levels, they found its involvement in pathways that signal the metabolism, growth, migration and invasion of tumor tissues. MicroRNA-218 is a tumor suppressor low miRNA-218 equals low function in a range of tumor suppressor genes, equals high tumor growth.

In fact, the group found 618 genes whose expression was manipulated by microRNA-218.

"One of these genes was CDK6," Vibhakar says. Finding a gene target is especially important because whereas it's difficult to drug microRNA it's fairly simple to drug genes. As it turned out, Pfizer already had a drug that targets CDK6 and in a follow-up study published in the Journal of NeuroOncology, when Vibhakar and colleagues tested the drug in medulloblastoma cells, they found reduced cancer cell survival.

"Especially important is
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related biology news :

1. Discovery of pathway leading to depression reveals new drug targets
2. Discovery of molecular pathway of Alzheimers disease reveals new drug targets
3. Naïve fish: Easy targets for spear fishers
4. New potential targets discovered for treating squamous cell lung cancers
5. Scientists use worms to unearth cancer drug targets
6. Wayne State University researchers program targets safer river fishing, anglers health
7. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
8. Its a trap! New laboratory technique captures microRNA targets
9. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
10. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
11. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 2012 Chemicals in the environment that mimic estrogen ... animals. New research to be presented at the 2012 ... in Madison, Wisconsin, reveals that these substances may act ... stages of embryonic development. Estrogenic compounds in the ...
... Autism Speaks, the world,s leading autism science and advocacy ... totaling nearly $2.9 million in funding to support autism ... Speaks, not only for funding research projects which have ... said Autism Speaks Co-founder Bob Wright, "but in supporting ...
... Mich.A dry spring in portions of the Midwest is expected ... on record in 2012, according to a University of Michigan ... 2012 Gulf of Mexico dead zone of about 1,200 square ... forecast is correct, 2012 would replace 2000 (1,696 square miles) ...
Cached Biology News:Environmental estrogens affect early developmental activity in zebrafish 2Environmental estrogens affect early developmental activity in zebrafish 3Autism Speaks awards nearly $2.9 million to fund autism research 2Autism Speaks awards nearly $2.9 million to fund autism research 3Autism Speaks awards nearly $2.9 million to fund autism research 4U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 2U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 3U-M forecasters predict second-smallest Gulf of Mexico 'dead zone' 4
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/24/2014)... Senior Vice President, General Manager ... skills, business acumen Elsevier , a ... and services, congratulates Diane Bartoli , Senior Vice ... Elsevier Clinical Solutions, for being recognized in the 13 ... issue of Profiles in Diversity Journal ® ...
(Date:11/22/2014)... November 21, 2014 Prominent academics, ... will gather on December 3rd at Genetic Rx, ... series. GeneticRx will take place at the Joseph ... and will discuss the present and future of ... skipping, and gene editing—as well as the treatment ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by type ... Plastic), by Application [GC, LC (HPLC, UHPLC, Flash ... analyses and studies the major market drivers, restraints, ... and Rest of the World. , Browse 90 ... 135 pages and in-depth TOC on “Chiral Chromatography ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... and WILMINGTON, Del., Sept. 22 For,his lifetime commitment ... of,radiation and other environmental exposures on the developing fetus ... education, Robert,L. Brent, MD, PhD, will be honored as ... for Excellence in Children,s Health Care by Nemours,one of ...
... Preclinical Research at Upcoming Conferences, CALGARY, Sept. ... ONCY) today announced the participation of five of ... conferences,through November 15, 2008 covering clinical trial results ... time for Oncolytics as we begin to share ...
... Names Industry Veteran as Executive Director, INDIANAPOLIS, ... management, clinical, and pharmaceutical testing facility,is announcing the ... industry veteran to lead the division. AIT has ... of West Lafayette-based,Bioanalytical Systems, Inc. (Nasdaq: BASI ...
Cached Biology Technology:Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Children's Health Care 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 3AIT Laboratories Expands Pharma Services 2AIT Laboratories Expands Pharma Services 3
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Biology Products: